Litigation Details for Journey Medical Corporation v. Padagis Israel Pharmaceuticals, Ltd. (D. Del. 2021)
✉ Email this page to a colleague
Journey Medical Corporation v. Padagis Israel Pharmaceuticals, Ltd. (D. Del. 2021)
| Docket | ⤷ Try a Trial | Date Filed | 2021-08-09 |
| Court | District Court, D. Delaware | Date Terminated | 2022-05-19 |
| Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
| Jury Demand | None | Referred To | |
| Parties | VYNE THERAPEUTICS INC. | ||
| Patents | 10,086,080; 10,137,200; 10,213,512; 10,265,404; 10,398,641; 10,517,882; 8,865,139; 8,945,516; 8,992,896; 9,675,700 | ||
| Attorneys | Jonathan R. Davies | ||
| Firms | Shaw Keller LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Journey Medical Corporation v. Padagis Israel Pharmaceuticals, Ltd.
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .
Biologic Drugs cited in Journey Medical Corporation v. Padagis Israel Pharmaceuticals, Ltd.
The biologic drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for Journey Medical Corporation v. Padagis Israel Pharmaceuticals, Ltd. (D. Del. 2021)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2021-08-09 | 1 | Complaint | (“the ’896 patent”); 9,675,700 (“the ’700 patent”); 10,086,080 (“the ’080 patent”); 10,137,200 (“the… COUNT IX – INFRINGEMENT OF U.S. PATENT NO. 10,086,080 93. Plaintiff fully incorporate…’139 patent, the ’516 patent, the ’896 patent, the ’700 patent, the ’080 patent, the ’200 patent, the…’139 patent, the ’516 patent, the ’896 patent, the ’700 patent, the ’080 patent, the ’200 patent, the…’139 patent, the ’516 patent, the ’896 patent, the ’700 patent, the ’080 patent, the ’200 patent, the | External link to document |
| 2021-08-09 | 3 | ANDA Form | Expiration of Patent: Patent Nos. 8,865,139; 8,945,516; 8,992,896; 9,675,700; 10,086,080; 10,137,200; … Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …10,517,882; and 10,821,187 expire on 10/01/2030. Patent Nos. 10,398,641 and 10,849,847 will expire on 09… 2021 19 May 2022 1:21-cv-01152 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2021-08-09 | 4 | Patent/Trademark Report to Commissioner of Patents | ;8,945,516 B2 ;8,992,896 B2 ;9,675,700 B2 ;10,086,080 B2 ;10,137,200 B2 ;10,213,512 B2 ;10,265,404 B2… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,865,139 B1 ;… 2021 19 May 2022 1:21-cv-01152 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2022-05-19 | 45 | Patent/Trademark Report to Commissioner of Patents | ; 8,945,516 B2; 8,992,896 B2; 9,675,700 B2; 10,086,080 B2. (Attachments: # 1 Stipulation of Dismissal)… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,865,139 B1; … 2021 19 May 2022 1:21-cv-01152 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
